MedDataX Logo

A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

NCT ID: NCT03739840

Last Updated: 2022-12-21

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

232 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-06

Study Completion Date

2020-09-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate the efficacy, safety and tolerability of the 3 selected dose regimens of padsevonil (PSL) administered concomitantly with up to 3 anti-epileptic drugs (AEDs) compared with placebo for treatment of observable focal-onset seizures in subjects with drug-resistant epilepsy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Drug-Resistant Epilepsy Focal-Onset Seizures

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Epilepsy Padsevonil

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Padsevonil dosing regimen 1

Subjects will be randomized to receive a combination of tablets of padsevonil and placebo (as appropriate) to maintain the blinding.

Group Type EXPERIMENTAL

Padsevonil

Intervention Type DRUG

Padsevonil in different dosages.

Placebo

Intervention Type DRUG

Placebo will be provided matching padsevonil.

Padsevonil dosing regimen 2

Subjects will be randomized to receive a combination of tablets of padsevonil and placebo (as appropriate) to maintain the blinding.

Group Type EXPERIMENTAL

Padsevonil

Intervention Type DRUG

Padsevonil in different dosages.

Placebo

Intervention Type DRUG

Placebo will be provided matching padsevonil.

Padsevonil dosing regimen 3

Subjects will be randomized to receive a combination of tablets of padsevonil and placebo (as appropriate) to maintain the blinding.

Group Type EXPERIMENTAL

Padsevonil

Intervention Type DRUG

Padsevonil in different dosages.

Placebo

Intervention Type DRUG

Placebo will be provided matching padsevonil.

Placebo

Subjects randomized to the placebo group will receive a combination of several placebo tablets to maintain the blinding.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo will be provided matching padsevonil.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Padsevonil

Padsevonil in different dosages.

Intervention Type DRUG

Placebo

Placebo will be provided matching padsevonil.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of focal epilepsy per 1989 International League Against Epilepsy (ILAE) criteria at least 3 years before study entry
* Subject has failed to achieve seizure control with \>=4 tolerated and appropriately chosen prior antiepileptic drugs (AED), including past and ongoing treatment, that were individually optimized for adequate dose and duration. Prior discontinued AED treatment would need to be assessed by the Investigator considering the patient medical records and patient and/or caregiver interview. 'Prior AED' is defined as all past and ongoing AED treatments with a start date before the Screening Visit (Visit 1)
* Average of \>= 4 spontaneous and observable focal seizures (type IA1 (i.e. focal aware), IB (i.e. focal impaired awareness), IC (i.e. focal to bilateral tonic-clonic)) per month
* Current treatment with an individually optimized and stable dose of at least 1 and up to 3 AEDs for the 8 weeks prior to the Screening Visit with or without additional Vagus Nerve Stimulation (VNS) or other neurostimulation treatments

Exclusion Criteria

* Subject has a history of or signs of generalized or combined generalized and focal epilepsy
* Cluster seizures which are uncountable in the previous 8 weeks before study entry and during 4 weeks prospective baseline
* Current treatment with carbamazepine, phenytoin, primidone, phenobarbital
* Current treatment/ use of (non-AED) prescription, nonprescription, dietary (eg, grapefruit or passion fruit), or herbal products that are potent inducers or inhibitors of the CYP3A4 or 2C19 pathway for 2 weeks (or 5 half-lives, whichever is longer) prior to the Baseline Visit
* Subjects taking sensitive substrates of CYP2C19 for 2 weeks (or 5 half-lives, whichever is longer) prior to the Baseline Visit
* Subject has been taking vigabatrin less than 2 years at study entry
* Subject has been taking felbamate for less than 12 months
* Subject taking retigabine for less than 4 years
* Current treatment with benzodiazepines (i.e. GABA-A-ergic drugs like zolpidem, zaleplon, or zopiclone, excluding GABA-A-ergic AEDs) \<3 times per week for emergencies
* Subject has a current medical condition that occurred within the last 12 months which, in the opinion of the investigator, could compromise his/her safety or ability to participate in this study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

UCB Biopharma SRL

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

UCB Cares

Role: STUDY_DIRECTOR

001 844 599 2273 (UCB)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ep0092 839

Chandler, Arizona, United States

Site Status

Ep0092 881

Tucson, Arizona, United States

Site Status

Ep0092 633

Carlsbad, California, United States

Site Status

Ep0092 629

Orange, California, United States

Site Status

Ep0092 845

Washington D.C., District of Columbia, United States

Site Status

Ep0092 892

Bradenton, Florida, United States

Site Status

Ep0092 640

Hialeah, Florida, United States

Site Status

Ep0092 641

Jacksonville, Florida, United States

Site Status

Ep0092 823

Orlando, Florida, United States

Site Status

Ep0092 803

Honolulu, Hawaii, United States

Site Status

Ep0092 637

Urbana, Illinois, United States

Site Status

Ep0092 880

Anderson, Indiana, United States

Site Status

Ep0092 638

Fort Wayne, Indiana, United States

Site Status

Ep0092 630

Ames, Iowa, United States

Site Status

Ep0092 707

Lexington, Kentucky, United States

Site Status

Ep0092 822

Baltimore, Maryland, United States

Site Status

Ep0092 818

Bethesda, Maryland, United States

Site Status

Ep0092 889

Boston, Massachusetts, United States

Site Status

Ep0092 645

Golden Valley, Minnesota, United States

Site Status

Ep0092 644

Minneapolis, Minnesota, United States

Site Status

Ep0092 878

Brooklyn, New York, United States

Site Status

Ep0092 876

New York, New York, United States

Site Status

Ep0092 893

Syracuse, New York, United States

Site Status

Ep0092 895

The Bronx, New York, United States

Site Status

Ep0092 890

Chapel Hill, North Carolina, United States

Site Status

Ep0092 884

Charlotte, North Carolina, United States

Site Status

Ep0092 642

Columbus, Ohio, United States

Site Status

Ep0092 647

Oklahoma City, Oklahoma, United States

Site Status

Ep0092 882

Portland, Oregon, United States

Site Status

Ep0092 802

Philadelphia, Pennsylvania, United States

Site Status

Ep0092 829

Charlottesville, Virginia, United States

Site Status

Ep0092 639

Renton, Washington, United States

Site Status

Ep0092 855

Box Hill, , Australia

Site Status

Ep0092 861

Camperdown, , Australia

Site Status

Ep0092 850

Fitzroy, , Australia

Site Status

Ep0092 853

Heidelberg, , Australia

Site Status

Ep0092 852

Melbourne, , Australia

Site Status

Ep0092 109

Brussels, , Belgium

Site Status

Ep0092 107

Ottignies, , Belgium

Site Status

Ep0092 080

Bihać, , Bosnia and Herzegovina

Site Status

Ep0092 077

Mostar, , Bosnia and Herzegovina

Site Status

Ep0092 075

Sarajevo, , Bosnia and Herzegovina

Site Status

Ep0092 082

Tuzla, , Bosnia and Herzegovina

Site Status

Ep0092 150

Blagoevgrad, , Bulgaria

Site Status

Ep0092 151

Pleven, , Bulgaria

Site Status

Ep0092 156

Pleven, , Bulgaria

Site Status

Ep0092 154

Sofia, , Bulgaria

Site Status

Ep0092 125

Zagreb, , Croatia

Site Status

Ep0092 126

Zagreb, , Croatia

Site Status

Ep0092 127

Zagreb, , Croatia

Site Status

Ep0092 128

Zagreb, , Croatia

Site Status

Ep0092 254

Brno, , Czechia

Site Status

Ep0092 258

Ostrava, , Czechia

Site Status

Ep0092 250

Prague, , Czechia

Site Status

Ep0092 251

Prague, , Czechia

Site Status

Ep0092 016

Aarhus, , Denmark

Site Status

Ep0092 015

Odense, , Denmark

Site Status

Ep0092 276

Tallinn, , Estonia

Site Status

Ep0092 277

Tallinn, , Estonia

Site Status

Ep0092 275

Tartu, , Estonia

Site Status

Ep0092 027

Tampere, , Finland

Site Status

Ep0092 312

Lyon, , France

Site Status

Ep0092 310

Paris, , France

Site Status

Ep0092 301

Strasbourg, , France

Site Status

Ep0092 365

Berlin, , Germany

Site Status

Ep0092 362

Bernau, , Germany

Site Status

Ep0092 363

Bielefeld, , Germany

Site Status

Ep0092 350

Frankfurt, , Germany

Site Status

Ep0092 368

Jena, , Germany

Site Status

Ep0092 357

Leipzig, , Germany

Site Status

Ep0092 376

Regensburg, , Germany

Site Status

Ep0092 425

Ioannina, , Greece

Site Status

Ep0092 426

Thessaloniki, , Greece

Site Status

Ep0092 427

Thessaloniki, , Greece

Site Status

Ep0092 428

Thessaloniki, , Greece

Site Status

Ep0092 403

Budapest, , Hungary

Site Status

Ep0092 405

Debrecen, , Hungary

Site Status

Ep0092 404

Pécs, , Hungary

Site Status

Ep0092 035

Cork, , Ireland

Site Status

Ep0092 036

Dublin, , Ireland

Site Status

Ep0092 452

Milan, , Italy

Site Status

Ep0092 526

Asahikawa, , Japan

Site Status

Ep0092 501

Asaka, , Japan

Site Status

Ep0092 521

Bunkyō City, , Japan

Site Status

Ep0092 525

Bunkyō City, , Japan

Site Status

Ep0092 504

Hamamatsu, , Japan

Site Status

Ep0092 505

Hiroshima, , Japan

Site Status

Ep0092 513

Hōfu, , Japan

Site Status

Ep0092 507

Itami, , Japan

Site Status

Ep0092 531

Izumi, , Japan

Site Status

Ep0092 539

Kumamoto, , Japan

Site Status

Ep0092 533

Kure, , Japan

Site Status

Ep0092 514

Kyoto, , Japan

Site Status

Ep0092 512

Nagakute, , Japan

Site Status

Ep0092 522

Ōmura, , Japan

Site Status

Ep0092 530

Ōsaka-sayama, , Japan

Site Status

Ep0092 515

Saitama, , Japan

Site Status

Ep0092 508

Sapporo, , Japan

Site Status

Ep0092 527

Shinagawa-Ku, , Japan

Site Status

Ep0092 509

Shizuoka, , Japan

Site Status

Ep0092 529

Yonago, , Japan

Site Status

Ep0092 775

Sandvika, , Norway

Site Status

Ep0092 605

Katowice, , Poland

Site Status

Ep0092 616

Katowice, , Poland

Site Status

Ep0092 603

Krakow, , Poland

Site Status

Ep0092 614

Krakow, , Poland

Site Status

Ep0092 612

Lodz, , Poland

Site Status

Ep0092 610

Lublin, , Poland

Site Status

Ep0092 620

Lublin, , Poland

Site Status

Ep0092 606

Nowa Sól, , Poland

Site Status

Ep0092 611

Warsaw, , Poland

Site Status

Ep0092 615

Wroclaw, , Poland

Site Status

Ep0092 619

Zamość, , Poland

Site Status

Ep0092 618

Zgierz, , Poland

Site Status

Ep0092 952

Aveiro, , Portugal

Site Status

Ep0092 950

Matosinhos Municipality, , Portugal

Site Status

Ep0092 925

Bucharest, , Romania

Site Status

Ep0092 926

Bucharest, , Romania

Site Status

Ep0092 927

Târgu Mureş, , Romania

Site Status

Ep0092 327

Belgrade, , Serbia

Site Status

Ep0092 325

Novi Sad, , Serbia

Site Status

Ep0092 004

Bardejov, , Slovakia

Site Status

Ep0092 662

Alicante, , Spain

Site Status

Ep0092 651

Barcelona, , Spain

Site Status

Ep0092 652

Barcelona, , Spain

Site Status

Ep0092 658

Barcelona, , Spain

Site Status

Ep0092 674

Madrid, , Spain

Site Status

Ep0092 657

Valencia, , Spain

Site Status

Ep0092 676

Zaragoza, , Spain

Site Status

Ep0092 576

Gothenburg, , Sweden

Site Status

Ep0092 575

Linköping, , Sweden

Site Status

Ep0092 053

Zurich, , Switzerland

Site Status

Ep0092 913

Ankara, , Turkey (Türkiye)

Site Status

Ep0092 915

Antalya, , Turkey (Türkiye)

Site Status

Ep0092 900

Istanbul, , Turkey (Türkiye)

Site Status

Ep0092 906

Istanbul, , Turkey (Türkiye)

Site Status

Ep0092 909

Istanbul, , Turkey (Türkiye)

Site Status

Ep0092 908

Trabzon, , Turkey (Türkiye)

Site Status

Ep0092 766

Brighton, , United Kingdom

Site Status

Ep0092 750

Manchester, , United Kingdom

Site Status

Ep0092 764

Swansea, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria Canada China Mexico Netherlands United States Australia Belgium Bosnia and Herzegovina Bulgaria Croatia Czechia Denmark Estonia Finland France Germany Greece Hungary Ireland Italy Japan Norway Poland Portugal Romania Serbia Slovakia Spain Sweden Switzerland Turkey (Türkiye) United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Rademacher M, Toledo M, Van Paesschen W, Liow KK, Milanov IG, Esch ML, Wang N, MacPherson M, Byrnes WJ, Minh TDC, Webster E, Werhahn KJ. Efficacy and safety of adjunctive padsevonil in adults with drug-resistant focal epilepsy: Results from two double-blind, randomized, placebo-controlled trials. Epilepsia Open. 2022 Dec;7(4):758-770. doi: 10.1002/epi4.12656. Epub 2022 Oct 22.

Reference Type RESULT
PMID: 36176044 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2018-002303-33

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

EP0092

Identifier Type: -

Identifier Source: org_study_id